Gilead Begins Remdesivir Trials in the UK

Gilead has initiated two phase 3 clinical trials in the UK to test remdesivir for treatment of patients with COVID-19.

The two studies will initially involve 15 centers in the UK and will evaluate the antiviral’s safety and efficacy in moderate to severe COVID-19 patients.

Clinical trials of remdesivir are currently under way around the world, including in the U.S. Remdesivir is also included as one arm of the World Health Organization’s SOLIDARITY trial.